Literature DB >> 1909699

High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.

J Koberda1, L Bergmann, P S Mitrou, D Hoelzer.   

Abstract

Adherent lymphokine-activated killer cells (A-LAK) are highly potent cytotoxic cells, which are shown to be derived not only from natural killer (NK)/K cells but phenotypically also from T cells. The generation and phenotypical and functional characterisation of these T-cell-derived A-LAK are described. In contrast to non-adherent cells (NA-LAK) and unseparated LAK (UN-LAK), these mostly CD3+ CD56+ CD8+ cells display a high degree of expansion following initial interleukin-2 (rIL-2) activation and further culturing in autologous conditioned medium. A comparison of cytotoxic activities of cultured cells reveals a significantly higher oncolytic ability of A-LAK cells against both K562 and Daudi cells than that of cultured controls of NA-LAK and UN-LAK. In addition, A-LAK are characterised by a marked endogenous cytokine release of interferon gamma, tumour necrosis factor alpha and IL-6 as well as by their shedding of p55 IL-2 receptor after exposure to IL-2. The results demonstrate A-LAK to be the lymphocyte subpopulation with the most cytotoxic activity and endogenous cytokine release after exposure to IL-2. The improvement of techniques for long-term cultures may be of interest for future therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909699     DOI: 10.1007/bf01612762

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  23 in total

1.  Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.

Authors:  L Bergmann; E Weidmann; P S Mitrou; U Runne; U Keilholz; H H Bartsch; C R Franks
Journal:  Onkologie       Date:  1990-04

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  Generation and characterization of purified adherent lymphokine-activated killer cells in mice.

Authors:  Y Gunji; N L Vujanovic; J C Hiserodt; R B Herberman; E Gorelik
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

4.  Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.

Authors:  R E Schwarz; N L Vujanovic; J C Hiserodt
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

Review 5.  Analysis of effector mechanisms in cancer.

Authors:  E Lotzová
Journal:  Curr Opin Immunol       Date:  1989-06       Impact factor: 7.486

6.  Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.

Authors:  C Verfaillie; W Miller; N Kay; P McGlave
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

7.  Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.

Authors:  S C Yang; L B Owen-Schaub; J A Roth; E A Grimm
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

8.  Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors.

Authors:  R E Schwarz; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.

Authors:  T L Whiteside; Y L Wang; R G Selker; R B Herberman
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

10.  Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.

Authors:  N L Vujanovic; R B Herberman; A A Maghazachi; J C Hiserodt
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more
  2 in total

1.  In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.

Authors:  B Jahn; J Brieger; K Fenchel; P S Mitrou; L Bergmann
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

2.  Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.

Authors:  I Vollenweider; R Moser; P Groscurth
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.